Introducing Apollo Therapeutics
Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, University College London and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). It provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.
Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success. Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes.
Apollo Projects
- Influencing the immunological microenvironment through TRAIL-R2 Fc fusion Richard Butt 2019-01-30T16:45:28+00:00
- Maintaining normal vWF function whilst inhibiting aberrant effects Richard Butt 2019-02-21T16:34:15+00:00
- Preventing Reperfusion Injury Through Inhibition of ROS Function Richard Butt 2019-06-24T11:12:49+01:00
- Inhibiting neurodegeneration and CNS driven disease in a rare disease ciliopathy Richard Butt 2019-02-18T10:59:22+00:00
- Aurora A-TPX2 interaction inhibitors to drive selective inhibition of Aurora A and protein degradation pathways Richard Butt 2019-01-04T15:45:56+00:00
- Targeting viral packaging, a highly conserved process in HIV lifecycle as a novel anti-viral Richard Butt 2018-10-09T12:24:54+01:00
- Selective CDK2 inhibition through a novel, allosteric binding site with covalent inhibitors Richard Butt 2019-01-02T11:42:40+00:00
- Muller cell therapy to enhance retinal ganglion cell function Richard Butt 2019-01-04T16:15:46+00:00
- Epigenetically programming T cell phenotype for enhanced efficacy Richard Butt 2019-01-02T11:44:43+00:00
- Influencing the immunological microenvironment through TRAIL-R2 Fc fusion Richard Butt 2019-01-30T16:45:28+00:00
- Maintaining normal vWF function whilst inhibiting aberrant effects Richard Butt 2019-02-21T16:34:15+00:00
- Preventing Reperfusion Injury Through Inhibition of ROS Function Richard Butt 2019-06-24T11:12:49+01:00
- Inhibiting neurodegeneration and CNS driven disease in a rare disease ciliopathy Richard Butt 2019-02-18T10:59:22+00:00
- Aurora A-TPX2 interaction inhibitors to drive selective inhibition of Aurora A and protein degradation pathways Richard Butt 2019-01-04T15:45:56+00:00
- Targeting viral packaging, a highly conserved process in HIV lifecycle as a novel anti-viral Richard Butt 2018-10-09T12:24:54+01:00
- Selective CDK2 inhibition through a novel, allosteric binding site with covalent inhibitors Richard Butt 2019-01-02T11:42:40+00:00
- Muller cell therapy to enhance retinal ganglion cell function Richard Butt 2019-01-04T16:15:46+00:00
- Epigenetically programming T cell phenotype for enhanced efficacy Richard Butt 2019-01-02T11:44:43+00:00
Apollo People
The drug discovery team are highly experienced applied scientists with expertise in the discovery and development of new experimental drugs from a range of modalities and therapeutic indications. The drug discovery team will work with academic scientists from each of the Universities to identify the best translational targets and to prosecute and deliver a pipeline of products for licensing
The investment committee has sole responsibility for reviewing and endorsing the project proposals, plans, costs, timelines and licensing strategy proposed by the drug discovery team
The LLP Committee have responsibility for the management and control of Apollo, including approval of the business plan, the annual budget and the setting of various key governance policies
The Scientific Advisory board will meet annually and advise Apollo on science, portfolio and relevant emerging trends and priorities in the Biopharm and University environments
Apollo News
Apollo Therapeutics News & Press Releases
Why can’t we cure the common cold?
The common cold has the twin distinction of being both the world’s most widespread infectious disease and one of the most elusive… READ THE FULL GUARDIAN ARTICLE HERE […]
Apollo Therapeutics shortlisted for Biotech and Money’s ‘Life Science Spin-out of the Year’
Stevenage, 12 June 2017: Apollo Therapeutics (‘Apollo’), the collaborative venture between three world-leading UK universities and three global pharmaceutical companies, is pleases to announce that it has been shortlisted as a finalist in the ‘UK Life Science Spin-Out of the Year’ category of the Biotech and Money 2017 Awards.
Funding of four initial projects and operational update
First four drug discovery programmes now launched in collaboration with academics at all three partner universities - spanning a variety of disease areas and drug modalities Recruited highly experienced Project Directors with track records of [...]
